Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Coherus Biosciences (CHRS – Research Report) and keeping the price target at $7.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Douglas Tsao has given his Buy rating due to a combination of factors that suggest a positive outlook for Coherus Biosciences. Despite a temporary setback in the commercial momentum of Loqtorzi, a drug for nasopharyngeal carcinoma, the company has achieved significant milestones, such as the inclusion of Loqtorzi in the National Comprehensive Cancer Network’s revised guidelines as the preferred regimen. This endorsement is expected to enhance the drug’s adoption among specialists.
Furthermore, Coherus Biosciences has reported a 15% growth in end-user demand for Loqtorzi in the first quarter of 2025, with 75 new accounts purchasing the drug. The company anticipates accelerated growth in the upcoming quarters, supported by increased awareness efforts. Coherus projects substantial revenue growth, estimating $150M-$200M annually from the NPC indication alone over the next three years. These factors collectively underpin Tsao’s optimistic Buy rating for the stock.